Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.

MLA

Holmgaard, Rikke B., et al. “Targeting the TGFβ Pathway with Galunisertib, a TGFβRI Small Molecule Inhibitor, Promotes Anti-Tumor Immunity Leading to Durable, Complete Responses, as Monotherapy and in Combination with Checkpoint Blockade.” Journal for ImmunoTherapy of Cancer, vol. 6, no. 1, June 2018, p. N.PAG. EBSCOhost, https://doi.org/10.1186/s40425-018-0356-4.

APA

Holmgaard, R. B., Schaer, D. A., Li, Y., Castaneda, S. P., Murphy, M. Y., Xu, X., Inigo, I., Dobkin, J., Manro, J. R., Iversen, P. W., Surguladze, D., Hall, G. E., Novosiadly, R. D., Benhadji, K. A., Plowman, G. D., Kalos, M., & Driscoll, K. E. (2018). Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade. Journal for ImmunoTherapy of Cancer, 6(1), N.PAG. https://doi.org/10.1186/s40425-018-0356-4

Chicago

Holmgaard, Rikke B., David A. Schaer, Yanxia Li, Stephen P. Castaneda, Mary Y. Murphy, Xiaohong Xu, Ivan Inigo, et al. 2018. “Targeting the TGFβ Pathway with Galunisertib, a TGFβRI Small Molecule Inhibitor, Promotes Anti-Tumor Immunity Leading to Durable, Complete Responses, as Monotherapy and in Combination with Checkpoint Blockade.” Journal for ImmunoTherapy of Cancer 6 (1): N.PAG. doi:10.1186/s40425-018-0356-4.